OraSure Technologies is launching its at-home HIV diagnostic test in retail pharmacies, including CVS Caremark and Walgreen. The company's share price increased during intra-day trading, and investors are waiting to see how well this product sells. OraSure is promoting the product through a massive marketing effort and will have support from a celebrity spokesperson.

In the following video, health-care analysts Max Macaluso and David Williamson discuss the potential impact of this marketing campaign on OraSure's sales and future stock performance.

OraSure will be an interesting stock to follow in the upcoming quarters, but are you looking to add other growth stocks to your portfolio? Our new report "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice" highlights three less-than-luxurious stocks the 1% may be overlooking. Just click here to read it today.

The article Will Marketing Make the Difference for OraSure? originally appeared on Fool.com.

Max Macaluso, David Williamson, and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Small Cap Investing

Learn now to invest in small companies the right way.

View Course »

Asset Allocation

Learn the most important step in structuring an investment portfolio.

View Course »

Add a Comment

*0 / 3000 Character Maximum